NCT06223516 2026-03-11
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
Clinical Trials
9 trialsNCT07260708 2025-12-19
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT07179679 2025-12-11
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT07110194 2025-08-07
Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting
NCT07036185 2025-06-25
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
Shanghai Bao Pharmaceuticals Co., Ltd.
Phase 1 Not yet recruiting
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT00833326 2020-10-06
A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT00462358 2020-09-28
A Study of ARRY-520 in Patients With Advanced Cancer
Array BioPharma
Phase 1 Completed